68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively PET-MRI, in patients with prostate cancer. PET uses a radioactive substance called 68Ga-DOTA-Bombesin, which attaches to tumor cells with specific receptors on their surfaces. The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy prostate tissue. MRI uses radio waves and a magnet to make a picture of areas inside the body. Using 68Ga-DOTA-Bombesin in diagnostic procedures, such as PET/MRI, may allow doctors to identify smaller tumors than standard imaging.

Official Title

68Ga-DOTA-Bombesin PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No


Andrei Iagaru
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)

Contact us to find out if this trial is right for you.